Acrodermatitis chronica atrophicans natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Acrodermatitis chronica atrophicans Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Acrodermatitis chronica atrophicans from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acrodermatitis chronica atrophicans natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acrodermatitis chronica atrophicans natural history, complications and prognosis
CDC on Acrodermatitis chronica atrophicans natural history, complications and prognosis
Acrodermatitis chronica atrophicans natural history, complications and prognosis in the news
Blogs on Acrodermatitis chronica atrophicans natural history, complications and prognosis
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Acrodermatitis chronica atrophicans natural history, complications and prognosis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Natural History

The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.

Prognosis

The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.